<DOC>
	<DOCNO>NCT01882868</DOCNO>
	<brief_summary>Primary Objective : To assess efficacy aflibercept + 5-fluorouracil ( 5-FU ) /levofolinate/irinotecan ( FOLFIRI ) objective response rate ( ORR ) . Secondary Objective : To assess follow : - safety profile ; - progression free survival ( PFS ) ; - overall survival ( OS ) ; - pharmacokinetics ( PK ) ; - immunogenicity .</brief_summary>
	<brief_title>A Study Aflibercept Combination With FOLFIRI Patients With Second-Line Metastatic Colorectal Cancer Japan</brief_title>
	<detailed_description>Screening 24 day . Treatment period continue DP , unacceptable toxicity , participant 's refusal . Follow period continue death , participant 's refusal , end study , whichever come first . This trial conduct Japan , International Nonproprietary Name ( INN ) designation study molecule `` aflibercept '' term therefore use throughout synopsis . In US , US proper name `` ziv-aflibercept '' .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>Inclusion criterion : Histologically cytologically proven adenocarcinoma colon rectum . Metastatic disease amenable potentially curative treatment . Participants measurable disease . One prior chemotherapeutic regimen ( contain oxaliplatin ) metastatic disease . Participants relapse within 6 month completion oxaliplatinbased adjuvant chemotherapy also eligible . Exclusion criterion : Prior therapy irinotecan . Less 28 day elapse prior radiotherapy , prior surgery , prior chemotherapy time registration . Unresolved toxicity ( grade &gt; 1 ) prior anticancer therapy . Eastern Cooperative Oncology Group ( ECOG ) performance status &gt; 1 . Brain metastasis , uncontrolled spinal cord compression , carcinomatous meningitis . Other prior malignancy . Pregnant breastfeed woman . Uncontrolled hypertension . Inadequate bone marrow function , liver function , renal function . The information intend contain consideration relevant participant 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>